newsfilter
← Latest News
Business Wire·

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023

Appili completes strategic reprioritization of programs to focus on ATI-1701, a biodefense tularemia vaccine candidate, ATI-1801, a topical antiparasitic product for the treatment of a disfiguring disease, and ATI-1501,